ホーム › トリプルネガティブ乳がん › ニューヨーク › New York City
New York City、NYにおけるトリプルネガティブ乳がんの臨床試験
New York Cityとその周辺地域（約30マイル以内）の拠点で、トリプルネガティブ乳がんに関する31件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- 他2件
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
被験者募集中第1相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- NYU Langone Medical Center, New York
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
被験者募集中第3相
- Laura and Isaac Perlmutter Cancer Center ( Site 0003), New York
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
被験者募集中第3相
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135), New York
- Icahn School of Medicine at Mount Sinai ( Site 0123), New York
- Memorial Sloan Kettering Cancer Center ( Site 0067), New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
被験者募集中第1相
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Mount Sinai, New York
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
被験者募集中第2相
- NYP/Weill Cornell Medical Center, New York
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
被験者募集中第3相
- Laura and Isaac Perlmutter Cancer Canter, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
被験者募集中第1相
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
被験者募集中第2相
- Memorial Sloan-Kettering Cancer Center (All Protocol Activities), New York
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center, New York
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
被験者募集中第2/3相
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center 53rd street., New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
被験者募集中第1相
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
被験者募集中早期第1相
- Mount Sinai Health System, New York
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- Laura and Isaac Perlmutter Cancer Center / NYU Langone Health, New York
- Columbia University Medical Center, New York
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
被験者募集中第1/2相
- NYU Langone perimutter Cancer Center, New York
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center, New York
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- NYU Langone Health, New York
他の都市におけるトリプルネガティブ乳がんの試験
- Houston, TX42件の研究
- Nashville, TN28件の研究
- Los Angeles, CA27件の研究
- Boston, MA26件の研究
- San Antonio, TX23件の研究
- St. Louis, MO21件の研究
- Arlington, VA20件の研究
- Atlanta, GA20件の研究
- Dallas, TX18件の研究
- Chicago, IL16件の研究
- Columbus, OH16件の研究
- Grand Rapids, MI15件の研究
New York Cityにおける他の研究
- 乳がん136件の研究
- 非小細胞肺癌121件の研究
- がん（全種類）109件の研究
- 前立腺がん103件の研究
- 転移性癌93件の研究
- 大腸癌78件の研究
- 卵巣がん69件の研究
- 肺がん60件の研究
- 多発性骨髄腫60件の研究
- 膵臓がん60件の研究
- 子宮内膜がん52件の研究
- 急性骨髄性白血病51件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。